[go: up one dir, main page]

EA005931B1 - Ингибиторы ароматазы и моноклональные антитела против her2 как противоопухолевые агенты - Google Patents

Ингибиторы ароматазы и моноклональные антитела против her2 как противоопухолевые агенты Download PDF

Info

Publication number
EA005931B1
EA005931B1 EA200201213A EA200201213A EA005931B1 EA 005931 B1 EA005931 B1 EA 005931B1 EA 200201213 A EA200201213 A EA 200201213A EA 200201213 A EA200201213 A EA 200201213A EA 005931 B1 EA005931 B1 EA 005931B1
Authority
EA
Eurasian Patent Office
Prior art keywords
aromatase inhibitor
hek2
antibody against
exemestane
hormone
Prior art date
Application number
EA200201213A
Other languages
English (en)
Russian (ru)
Other versions
EA200201213A1 (ru
Inventor
Джорджо Массимини
Габриелла Пишителли
Дайнеш Пурандаре
Original Assignee
Фармация Италия С.П.А.
Фармация Энд Апджон Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Фармация Италия С.П.А., Фармация Энд Апджон Компани filed Critical Фармация Италия С.П.А.
Publication of EA200201213A1 publication Critical patent/EA200201213A1/ru
Publication of EA005931B1 publication Critical patent/EA005931B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EA200201213A 2000-05-15 2001-04-19 Ингибиторы ароматазы и моноклональные антитела против her2 как противоопухолевые агенты EA005931B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57135500A 2000-05-15 2000-05-15
PCT/EP2001/004468 WO2001087334A1 (en) 2000-05-15 2001-04-19 Aromatase inhibitors and monoclonal anti-her2 antibodies as antitumors agents

Publications (2)

Publication Number Publication Date
EA200201213A1 EA200201213A1 (ru) 2003-04-24
EA005931B1 true EA005931B1 (ru) 2005-08-25

Family

ID=24283360

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200201213A EA005931B1 (ru) 2000-05-15 2001-04-19 Ингибиторы ароматазы и моноклональные антитела против her2 как противоопухолевые агенты

Country Status (20)

Country Link
EP (1) EP1282440A1 (et)
JP (1) JP2003533490A (et)
KR (1) KR20030014223A (et)
CN (1) CN1429118A (et)
AU (1) AU784617B2 (et)
BR (1) BR0110732A (et)
CA (1) CA2409652A1 (et)
CZ (1) CZ20023748A3 (et)
EA (1) EA005931B1 (et)
EE (1) EE200200622A (et)
HK (1) HK1054200A1 (et)
HU (1) HUP0301877A2 (et)
IL (1) IL152389A0 (et)
MX (1) MXPA02011194A (et)
NO (1) NO20025302L (et)
NZ (1) NZ523004A (et)
PL (1) PL360153A1 (et)
SK (1) SK16022002A3 (et)
WO (1) WO2001087334A1 (et)
ZA (1) ZA200209815B (et)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014015137A3 (en) * 2012-07-18 2014-03-13 Angion Biomedica Corp. Compositions and methods for treating dysproliferative diseases

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA9811162B (en) 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
AUPQ105799A0 (en) 1999-06-18 1999-07-08 Victor Chang Cardiac Research Institute, The Cell growth inhibition
KR20080038458A (ko) 2000-05-19 2008-05-06 제넨테크, 인크. ＥｒｂＢ 길항제에 의한 암 치료요법에 대한 효과적인반응의 가능성을 개선시키기 위한 유전자 검출 분석
EP1377298B1 (en) * 2001-01-26 2006-08-30 Pfizer Italia S.r.l. Exemestane for treating hormono-dependent disorders
GB2375958B (en) 2001-04-09 2005-03-02 George Margetts The use of steroids to lower the levels of cortisol
CN100424175C (zh) 2002-03-26 2008-10-08 上海泽生科技开发有限公司 ErbB-3 用于肿瘤治疗的方法和组合物
JP2005534679A (ja) * 2002-07-01 2005-11-17 サビエント ファーマシューティカルズ，インコーポレイティド 治療的処置のための組成物および方法
FR2844455B1 (fr) * 2002-09-13 2007-12-14 Lab Francais Du Fractionnement Traitement des pathologies echappant a la reponse immune par des anticorps optimises
WO2006008639A1 (en) * 2004-07-16 2006-01-26 Pfizer Products Inc. Combination treatment for non-hematologic malignancies using an anti-igf-1r antibody
PL1846030T3 (pl) 2005-01-21 2019-05-31 Genentech Inc Ustalone dawkowanie przeciwciał her
EP3195879A1 (en) 2005-02-23 2017-07-26 Genentech, Inc. Extending time to disease progression or survival in cancer patients
WO2007045027A1 (en) * 2005-10-19 2007-04-26 Chavah Pty Ltd Reduction of side effects from aromatase inhibitors used for treating breast cancer
WO2008109440A2 (en) 2007-03-02 2008-09-12 Genentech, Inc. Predicting response to a her dimerisation inhibitor based on low her3 expression
EP2592156B1 (en) 2007-06-08 2016-04-20 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
AR075896A1 (es) 2009-03-20 2011-05-04 Genentech Inc Anticuerpos anti-her (factor de crecimiento epidermico)
WO2010136569A1 (en) 2009-05-29 2010-12-02 F. Hoffmann-La Roche Ag Modulators for her2 signaling in her2 expressing patients with gastric cancer
CA2784211C (en) 2010-02-18 2019-12-24 Genentech, Inc. Neuregulin antagonists and use thereof in treating cancer
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
WO2012069466A1 (en) 2010-11-24 2012-05-31 Novartis Ag Multispecific molecules
SG191153A1 (en) 2010-12-23 2013-07-31 Hoffmann La Roche Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
CN102068429B (zh) * 2010-12-28 2011-12-14 西南大学 法倔唑在诱导罗非鱼已分化卵巢转变为功能型精巢中的应用及其诱导方法
CN103890007A (zh) 2011-08-17 2014-06-25 霍夫曼-拉罗奇有限公司 神经调节蛋白抗体及其用途
US9327023B2 (en) 2011-10-25 2016-05-03 The Regents Of The University Of Michigan HER2 targeting agent treatment in non-HER2-amplified cancers having HER2 expressing cancer stem cells
WO2013081645A2 (en) 2011-11-30 2013-06-06 Genentech, Inc. Erbb3 mutations in cancer
EP2788500A1 (en) 2011-12-09 2014-10-15 F.Hoffmann-La Roche Ag Identification of non-responders to her2 inhibitors
JP2015514710A (ja) 2012-03-27 2015-05-21 ジェネンテック， インコーポレイテッド Ｈｅｒ３阻害剤に関する診断及び治療
CA2889298C (en) 2012-11-30 2024-01-02 Anton Belousov Identification of patients in need of pd-l1 inhibitor cotherapy
WO2016061615A1 (en) 2014-10-22 2016-04-28 Chavah Pty Ltd Methods of reducing mammographic breast density and/or breast cancer risk
EP3364978A4 (en) 2015-10-22 2019-06-05 Havah Therapeutics Pty Ltd METHOD FOR REDUCING MAMMOGRAPHIC BREAST DENSITY AND / OR BREAST CANCER RISK
EP3454863A1 (en) 2016-05-10 2019-03-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Combinations therapies for the treatment of cancer
CN107417791B (zh) * 2017-08-17 2020-09-22 合肥瀚科迈博生物技术有限公司 抗人ErbB2双特异性抗体、其制备方法及用途
JP2022535827A (ja) 2019-06-03 2022-08-10 ハバ セラピューティクス ピーティワイ エルティディ アンドロゲン剤およびアロマターゼ阻害剤の送達のための医薬製剤およびシステム、ならびに使用のための方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA9811162B (en) * 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014015137A3 (en) * 2012-07-18 2014-03-13 Angion Biomedica Corp. Compositions and methods for treating dysproliferative diseases

Also Published As

Publication number Publication date
NZ523004A (en) 2004-09-24
EE200200622A (et) 2004-06-15
CA2409652A1 (en) 2001-11-22
EP1282440A1 (en) 2003-02-12
MXPA02011194A (es) 2003-03-10
KR20030014223A (ko) 2003-02-15
SK16022002A3 (sk) 2003-04-01
ZA200209815B (en) 2003-12-03
AU784617B2 (en) 2006-05-18
HK1054200A1 (zh) 2003-11-21
CZ20023748A3 (cs) 2003-04-16
CN1429118A (zh) 2003-07-09
AU5630901A (en) 2001-11-26
EA200201213A1 (ru) 2003-04-24
HUP0301877A2 (hu) 2003-09-29
PL360153A1 (en) 2004-09-06
JP2003533490A (ja) 2003-11-11
BR0110732A (pt) 2003-02-04
WO2001087334A1 (en) 2001-11-22
NO20025302D0 (no) 2002-11-05
NO20025302L (no) 2002-11-05
IL152389A0 (en) 2003-05-29

Similar Documents

Publication Publication Date Title
EA005931B1 (ru) Ингибиторы ароматазы и моноклональные антитела против her2 как противоопухолевые агенты
AU2012229147B2 (en) Use of inhibitors of EGFR-family receptors in the treatment of hormone refractory breast cancers
US20050032759A1 (en) Antitumor combined therapy
JP6185102B2 (ja) トリプルネガティブおよび基底様乳癌の治療におけるｅｒｂｂ３阻害剤の使用
PT616812E (pt) Combinacao de compostos anti-hormonais e moleculas de ligacao no tratamento do cancro
JP2022058676A (ja) Ｌｉｖ１－ａｄｃ及び化学療法剤を用いた併用療法
JP2023085422A (ja) 乳癌のためのＥｒｂＢ－２／ＥｒｂＢ－３二重特異性抗体と内分泌療法との組み合わせ
CN114650846A (zh) 用基于铂的试剂和抗组织因子抗体-药物偶联物的组合治疗癌症的方法
CN113473989A (zh) Sumo活化酶抑制剂和检查点抑制剂的施用
Tokuda et al. Compassionate use of humanized anti-HER2/neu protein, trastuzumab for metastatic breast cancer in Japan
Nozawa et al. Triple HER2-blockade with lapatinib, trastuzumab, and pertuzumab for treatment of HER2 positive metastatic breast cancer with lymphangitic carcinomatosis: A case study
CN121513160A (zh) 梭杆菌特异性抗菌肽在制备促进抗肿瘤免疫治疗功效的药物中的应用
NZ614427B2 (en) Use of inhibitors of egfr-family receptors in the treatment of hormone refractory breast cancers
Dickler ADVANCES IN ONCOLOGY

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU